Background Loiasis is a vector-borne disease in Central and West Africa. While there is still
uncertainty to what extent loiasis is responsible for population morbidity, individuals having
both loiasis and onchocerciasis have a high risk of fatal encephalopathy when treatment (ie,
ivermectin) for onchocerciasis is given. Therefore it is current policy that communities of high
loiasis-burden are excluded from mass drug administration programmes of ivermectin. To
address this treatment gap we present diagnostic scores, based on clinical and behavioural …

Background Loiasis is a vector-borne disease in Central and West Africa. While there is still
uncertainty to what extent loiasis is responsible for population morbidity, individuals having
both loiasis and onchocerciasis have a high risk of fatal encephalopathy when treatment (ie,
ivermectin) for onchocerciasis is given. Therefore it is current policy that communities of high
loiasis-burden are excluded from mass drug administration programmes of ivermectin. To
address this treatment gap we present diagnostic scores, based on clinical and behavioural …